Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

Documenti analoghi

• Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
  di: Anywaine, Zacchaeus, et al.
  Pubblicazione: (2019)
• Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
  di: Afolabi, Muhammed O, et al.
  Pubblicazione: (2022)
• Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
  di: Ishola, David, et al.
  Pubblicazione: (2022)
• Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda
  di: Kitonsa, Jonathan, et al.
  Pubblicazione: (2020)
• Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya.
  di: Borna A Nyaoke, et al.
  Pubblicazione: (2017-01-01)